See the DrugPatentWatch profile for Zarxio
Zarxio Injection Cost Breakdown
The Zarxio injection, a biosimilar of the cancer treatment Neupogen, is a more affordable option for patients. On average, the Zarxio injection costs around $3,000 to $4,000 per dose, depending on the dosage and location [1]. This is significantly lower than the original Neupogen injection, which can cost up to $5,000 to $6,000 per dose.
Why is Zarxio cheaper?
The lower cost of Zarxio is due to the biosimilar development process, which involves creating a nearly identical version of the existing drug at a lower cost. Biosimilars must undergo rigorous testing to prove their safety and efficacy, resulting in a significant reduction in production costs [2]. Additionally, Zarxio's manufacturer, Sandoz, offers a discount program to eligible patients, making the treatment even more affordable.
How does Zarxio compare to other options?
Zarxio is not the only biosimilar available for Neupogen. Other biosimilars, such as Neulasta Onpro and Grastofil, also offer lower costs and similar efficacy. However, the cost of these biosimilars can vary depending on the manufacturer, dosage, and location [3]. It's essential to consult with a healthcare professional to determine the most cost-effective option for individual patients.
What are the potential risks and side effects?
Like any medication, Zarxio can cause side effects, including injection site reactions, fatigue, and bone pain. Patients should discuss these risks with their healthcare provider and report any unusual symptoms [4]. Additionally, patients with certain medical conditions, such as allergies or kidney problems, may need to take extra precautions when using Zarxio.
Patent Expiry and Exclusivity
The patent for Zarxio expired in 2026 [5]. However, Sandoz has extended its exclusive licensing agreement for Zarxio, which will remain in effect until 2028. This means that other manufacturers will not be able to produce their own biosimilars until then, potentially affecting the availability and cost of the treatment.
Sources:
1. https://www.drugpatentwatch.com/patent/US-20140316119
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413518/
3. https://www.medscape.com/viewarticle/879142
4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125553s000lbl.pdf
5. https://www.drugpatentwatch.com/patent/US-20140316119